SHC1 Antibody

What is SHC1 and why is it important in cell signaling research?

SHC1 (SHC-transforming protein 1) functions as a ubiquitously expressed signaling adapter protein that links activated growth factor receptors to downstream signaling pathways . It plays a critical role in mediating EGFR signaling through phosphorylation and protein interactions, which defines the output from the EGFR pathway . The protein exists in three functionally distinct isoforms with molecular weights of 46 kDa, 52 kDa, and 66 kDa, all encoded from the same gene and sharing common structural elements but possessing several unique phosphorylation sites . SHC1's importance extends to its involvement in the RAS/Raf/MAPK pathway, where it promotes cell proliferation and differentiation through its SH2 domain and protein tyrosine phosphate binding (PTB) domain, which recognize activated receptor tyrosine kinases . The tyrosine residues in SHC1's CH1 domain become phosphorylated by tyrosine kinases and serve as docking sites for proteins such as Grb2, which then recruits SOS to activate Ras . This complex signaling role makes SHC1 a critical target for researchers studying cellular communication networks and disease mechanisms.

How do I choose the appropriate SHC1 antibody for my specific experimental application?

Selecting the appropriate SHC1 antibody requires careful consideration of several factors based on your experimental design. First, determine which isoform(s) of SHC1 you need to detect – whether all three (p46, p52, p66) or specific variants. For detection of all isoforms, antibodies like the mouse anti-SHC1 clone F02/2H5 or rabbit polyclonal NBP3-23392 are validated to recognize the 46/52/66 kDa bands corresponding to all SHC1 variants . Second, consider the experimental application: for Western blotting, antibodies with verified reactivity in this technique should be prioritized, such as clone O91H8, which is quality-tested for Western blotting at concentrations of 0.1-1.0 μg/ml . For immunoprecipitation, some antibodies like clone O91H8 have been verified for this application at recommended concentrations (2.0 μg/ml) . Third, examine the species reactivity – some antibodies only recognize human SHC1, while others (like NBP3-23392) cross-react with mouse, rat, and rabbit SHC1 . Finally, consider the antibody type (monoclonal vs. polyclonal) based on your need for specificity versus broader epitope recognition. For critical experiments, it's advisable to validate the antibody in your specific system before proceeding with larger-scale studies.

What are the key differences between the three SHC1 isoforms (p46, p52, p66) and how can antibodies distinguish them?

Most commercial antibodies detect all three isoforms simultaneously, as observed in Western blotting results where distinct bands appear at approximately 46, 52, and 66 kDa . For example, the mouse anti-SHC1 antibody clone F02/2H5 detects bands of approximately 51 kDa, 55 kDa, and 66 kDa in HeLa cell lysates , while NBP3-23392 detects all three isoforms in A431 cells . To distinguish between isoforms, researchers should run appropriate molecular weight markers and expect to see three distinct bands. If studying a specific isoform, researchers must carefully interpret results based on the molecular weight of the detected band and may need to perform additional validation experiments, such as using cells with known expression patterns of specific isoforms or knockout/knockdown controls for verification of specificity.

What are the optimal conditions for using SHC1 antibodies in Western blotting?

For optimal Western blotting results with SHC1 antibodies, several key parameters should be considered. First, regarding antibody dilution, manufacturer recommendations suggest working concentrations between 1:1000 and 1:4000 for most SHC1 antibodies . For example, the mouse anti-SHC1 antibody (F02/2H5) is recommended at 1:1000 dilution , while the rabbit polyclonal antibody (NBP3-23392) has been validated at both 1:1000 and 1:4000 dilutions in A431 cell lysates . Second, sample preparation is critical – cell lysates should be prepared under conditions that preserve SHC1 protein integrity and phosphorylation status, typically using RIPA or other appropriate lysis buffers containing protease and phosphatase inhibitors. Third, when running the gel, ensure sufficient separation in the 45-70 kDa range to distinguish between the three SHC1 isoforms (46, 52, and 66 kDa). Fourth, during transfer, optimize conditions for proteins in this molecular weight range (typically 100V for 60-90 minutes or overnight transfer at lower voltage). Finally, for detection, both chemiluminescence and fluorescence-based systems work well, with enhanced chemiluminescence reagents being commonly used as described in recent research protocols . When troubleshooting, remember that antibody specificity may vary between cell lines – for instance, the NBP3-23392 antibody detects SHC1 in human Jurkat, HeLa, and SKN-SH cells, as well as rat brain tissue and rabbit spleen fibroblasts .

How can I effectively use SHC1 antibodies for immunoprecipitation studies?

For effective immunoprecipitation (IP) of SHC1, the following methodological considerations are essential. First, select an antibody validated specifically for IP applications, such as clone O91H8, which has been verified for immunoprecipitation at a recommended concentration of 2.0 μg/ml . Second, optimize your cell lysis conditions to preserve protein-protein interactions – typically, non-denaturing lysis buffers (e.g., NP-40 or Triton X-100 based) containing protease and phosphatase inhibitors are preferred over harsher RIPA buffers when studying SHC1 interactions. Third, pre-clear your lysate with protein A/G beads to reduce non-specific binding. Fourth, when incubating your antibody with the lysate, allow sufficient time (typically 2-12 hours at 4°C) for efficient antigen capture. Fifth, for the precipitation step, use either direct antibody conjugation to beads or protein A/G beads for antibody capture, depending on your experimental design. Finally, when eluting and analyzing the immunoprecipitated SHC1, be prepared to detect all three isoforms (p46, p52, p66) unless your experiment specifically targets one isoform. For co-immunoprecipitation studies examining SHC1 binding partners, consider gentle washing conditions to preserve weaker interactions and validate findings using reverse co-IP approaches. Given SHC1's role as an adaptor protein that interacts with numerous signaling molecules, IP studies can reveal valuable information about context-specific protein complexes in different cellular conditions.

What considerations are important for immunocytochemistry/immunofluorescence using SHC1 antibodies?

When performing immunocytochemistry (ICC) or immunofluorescence (IF) with SHC1 antibodies, several methodological considerations are crucial for obtaining reliable results. First, fixation method significantly impacts epitope accessibility – paraformaldehyde fixation (typically 4%) has been successfully used with SHC1 antibodies as demonstrated in the ICC/IF of A431 cells with the NBP3-23392 antibody . Second, permeabilization conditions should be optimized; NP-40 has been effectively used with SHC1 antibodies in A431 cells , though Triton X-100 or methanol may be alternatives worth testing depending on your cell type. Third, appropriate blocking (typically with 5-10% serum or BSA) is essential to reduce background staining. Fourth, antibody concentration may differ from Western blotting applications – titration experiments should be performed to determine optimal dilutions for ICC/IF specifically. Fifth, consider the subcellular localization pattern expected for SHC1, which primarily exhibits cytoplasmic distribution but may show membrane association upon receptor activation or nuclear localization in certain contexts. Sixth, always include proper controls such as secondary-antibody-only controls to assess background, and if possible, SHC1 knockdown/knockout samples as negative controls. Finally, when performing co-localization studies with other proteins, select compatible antibody combinations (different host species) and appropriate fluorophores with minimal spectral overlap. For visualization, confocal microscopy is preferable to accurately assess the subcellular distribution patterns of SHC1 in relation to its binding partners.

How can SHC1 antibodies be used to study its role in cancer progression and immunotherapy response?

Recent research has established SHC1 as a valuable biomarker for studying cancer progression and immunotherapy response, particularly in clear cell renal cell carcinoma (ccRCC). High expression of SHC1 in ccRCC tissues correlates with poorer survival outcomes, making it an independent prognostic factor . Antibody-based methods, particularly Western blotting, have been instrumental in validating these findings by demonstrating elevated SHC1 protein levels in both ccRCC tissues and cell lines compared to normal counterparts .

For researchers investigating SHC1's role in cancer immunotherapy, multiple analytical approaches are recommended. First, Western blotting with validated SHC1 antibodies can quantify expression levels in patient samples and correlate them with clinical outcomes. Second, immunohistochemistry can assess SHC1 expression patterns within the tumor microenvironment. Third, co-immunoprecipitation studies can reveal SHC1's interactions with immune checkpoint regulators.

Analysis of SHC1 expression in relation to immune infiltration has revealed significant correlations with 7 types of immune cells and 7 immune pathways . This suggests that SHC1 antibodies can be valuable tools for characterizing the tumor immune microenvironment. Furthermore, when investigating immunotherapy response, researchers should note that patients with low SHC1 expression demonstrate higher immunophenoscores (IPS) across all four CTLA4/PD1 subgroups, indicating potentially better responses to immune checkpoint blockade therapy . These findings suggest that SHC1 antibody-based assays could serve as companion diagnostics for immunotherapy selection in future clinical applications.

What techniques can combine SHC1 antibody detection with phosphorylation status assessment?

Assessing SHC1 phosphorylation status alongside protein detection requires specialized techniques that preserve post-translational modifications. First, for Western blotting approaches, researchers should use phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) in lysis buffers and maintain samples at cold temperatures to preserve phosphorylation sites. Phospho-specific SHC1 antibodies that target known phosphorylation sites (particularly tyrosine residues in the CH1 domain) can be used alongside total SHC1 antibodies in parallel blots or sequential reprobing of the same membrane after stripping.

Third, for microscopy techniques, dual immunofluorescence staining with total SHC1 and phospho-specific antibodies can reveal subcellular localization changes associated with phosphorylation. This is particularly relevant given SHC1's role in receptor tyrosine kinase signaling, where phosphorylation affects its interactions with proteins such as Grb2 .

Fourth, more advanced techniques such as Phos-tag SDS-PAGE can separate phosphorylated from non-phosphorylated SHC1 based on mobility shifts, followed by standard antibody detection. Finally, mass spectrometry following SHC1 immunoprecipitation can provide comprehensive mapping of phosphorylation sites when studying novel regulatory mechanisms. These combined approaches provide a more complete picture of SHC1's functional state in different experimental contexts.

How can I design experiments to investigate SHC1 isoform-specific functions using available antibodies?

Designing experiments to investigate isoform-specific functions of SHC1 requires strategic approaches given that most antibodies detect all three isoforms (p46, p52, p66). First, selective gene silencing can be employed using isoform-specific siRNAs or shRNAs that target unique regions of each isoform, followed by Western blot validation using SHC1 antibodies to confirm selective knockdown. This approach allows researchers to observe phenotypic changes associated with depletion of specific isoforms.

Second, overexpression studies using isoform-specific constructs (with appropriate tags if needed) can complement knockdown experiments. After transfection, researchers can use SHC1 antibodies to confirm overexpression and assess functional outcomes. For example, if investigating the reported role of p52 in breast cancer initiation , researchers could overexpress this specific isoform in relevant cell lines.

Third, for studying protein interactions, immunoprecipitation with SHC1 antibodies followed by mass spectrometry can identify isoform-specific binding partners when combined with isoform-selective expression systems. Additionally, proximity ligation assays (PLA) using SHC1 antibodies together with antibodies against suspected interaction partners can visualize interactions in situ.

What are common issues when working with SHC1 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with SHC1 antibodies. First, non-specific bands may appear in Western blots, particularly in the 45-70 kDa range where SHC1 isoforms are detected. To address this, optimization of antibody concentration is crucial—titration experiments comparing dilutions from 1:1000 to 1:4000 have been effective for antibodies like NBP3-23392 . Additionally, more stringent washing conditions or alternative blocking reagents (switching between milk and BSA) may reduce background.

Second, variability in isoform detection can occur between samples or experiments. This may relate to cell type-specific expression patterns or experimental conditions affecting isoform stability. For instance, while some antibodies detect all three isoforms in A431 cells , expression patterns may differ in other cell types. To address this, researchers should include positive control lysates from cells known to express all three isoforms (e.g., A431, HeLa, or Jurkat cells) .

Third, phosphorylation-dependent epitope masking may affect antibody binding, particularly if the antibody recognition site is near phosphorylation sites in the CH1 domain. Treatment with phosphatases prior to immunodetection can help determine if this is occurring. Alternatively, selecting antibodies targeting regions distant from known phosphorylation sites can mitigate this issue.

Fourth, for immunoprecipitation challenges such as poor pull-down efficiency, pre-clearing lysates, optimizing antibody-to-lysate ratios, and extending incubation times (overnight at 4°C) can improve results. Finally, for immunofluorescence applications with high background, additional blocking steps, reduced primary antibody concentration, and more extensive washing can enhance signal-to-noise ratio. In all applications, including appropriate negative controls (secondary antibody only, isotype controls, or knockdown samples) is essential for validating specificity.

How should I interpret conflicting results between different SHC1 antibodies?

When confronted with conflicting results between different SHC1 antibodies, systematic analysis is essential for accurate interpretation. First, examine epitope differences: antibodies targeting different regions of SHC1 may yield varied results due to epitope accessibility or post-translational modifications. For instance, some antibodies target the C-terminal region (e.g., NBP3-23392 targets the C-terminal region of human SHC1) , while others like F02/2H5 recognize amino acids 484-583 . Epitopes within functional domains such as SH2 or PTB might be masked during protein interactions.

Second, consider antibody format and host species differences. Monoclonal antibodies (like F02/2H5 or O91H8) offer high specificity but may fail if their epitope is altered, while polyclonal antibodies (like NBP3-23392) recognize multiple epitopes but might show more cross-reactivity. To address this, validation with multiple antibodies of different formats is recommended.

Third, evaluate technical variations in experimental conditions. Differences in sample preparation, buffer composition, or detection methods can significantly impact results. For instance, comparative Western blot analysis with rabbit polyclonal and mouse monoclonal SHC1 antibodies at different dilutions (1:1000 vs. 1:4000) has revealed variation in band intensity and detection sensitivity .

Fourth, perform validation experiments using positive and negative controls. Known SHC1-expressing cell lines (A431, HeLa, Jurkat) serve as positive controls, while knockdown/knockout samples provide negative controls. When interpretations remain unclear, orthogonal methods (RT-PCR, mass spectrometry) can validate protein identity and expression levels. Finally, consult published validation data and consider reaching out to antibody manufacturers for technical support when persistent discrepancies occur.

What statistical approaches are recommended for quantifying SHC1 expression in patient samples for prognostic studies?

For quantifying SHC1 expression in patient samples for prognostic studies, several statistical approaches have proven effective based on recent research. First, when analyzing SHC1 protein levels from Western blots, densitometric quantification should be normalized to loading controls (β-actin, GAPDH) and expressed as relative intensity units. For comparison between tumor and normal tissues, paired t-tests or Wilcoxon signed-rank tests are appropriate depending on data distribution .

Second, for stratifying patients in survival analyses, researchers have successfully employed median expression as a cutoff to divide patients into high and low SHC1 expression groups . This approach allows for Kaplan-Meier survival curve generation and log-rank tests to compare survival differences. In recent ccRCC studies, patients with low SHC1 expression demonstrated significantly higher survival rates, establishing SHC1 as an independent prognostic factor .

Fourth, when correlating SHC1 expression with immune infiltration, ssGSEA (single-sample Gene Set Enrichment Analysis) scores can quantify associations between SHC1 and immune cell types or pathways . Additional approaches include CIBERSORT algorithm for examining relationships with 22 types of immune cells and TIDE analysis for evaluating immune escape mechanisms . For immunotherapy response prediction, immunophenoscores (IPS) stratified by SHC1 expression provide valuable insights into potential treatment sensitivity . These comprehensive statistical approaches allow robust prognostic evaluation of SHC1 in clinical contexts.

What emerging technologies might enhance SHC1 antibody applications in research?

Several emerging technologies hold promise for expanding SHC1 antibody applications in research. First, multiplexed imaging techniques such as Imaging Mass Cytometry (IMC) and CODEX (CO-Detection by indEXing) could revolutionize SHC1 visualization in tissues by simultaneously detecting dozens of proteins, enabling comprehensive mapping of SHC1 interactions within the tumor microenvironment. These approaches would be particularly valuable given SHC1's recently established connections to immune infiltration in cancers like ccRCC .

Second, proximity-based protein interaction detection methods such as proximity ligation assay (PLA) and BioID could advance our understanding of SHC1's dynamic interactions with signaling partners. These techniques would enable researchers to visualize and identify transient interactions that traditional co-immunoprecipitation might miss, potentially revealing novel SHC1-dependent signaling networks.

Third, CRISPR-based technologies coupled with antibody detection could enable precise genome editing to modify SHC1 at specific residues while monitoring consequent protein expression and location changes. CRISPR knock-in approaches could tag endogenous SHC1 with reporters for live-cell imaging without overexpression artifacts.

Fourth, single-cell proteomics using antibody-based detection could reveal cell-to-cell variability in SHC1 expression and phosphorylation status within heterogeneous tumor populations. This would provide unprecedented resolution of SHC1's role in tumor biology beyond bulk tissue analysis. Finally, nanobody and recombinant antibody fragment technologies offer opportunities for developing smaller, more versatile SHC1-targeting reagents with potentially superior tissue penetration for imaging applications and reduced immunogenicity for potential therapeutic applications. These emerging technologies collectively promise to enhance our ability to study SHC1's complex roles in cell signaling and disease processes.

How might SHC1 antibodies contribute to the development of novel cancer biomarkers or therapeutics?

SHC1 antibodies have significant potential to contribute to novel cancer biomarkers and therapeutics based on recent discoveries of SHC1's role in tumor progression and immunotherapy response. First, for diagnostic and prognostic biomarker development, antibody-based immunohistochemistry assays could be standardized to assess SHC1 expression in tumor biopsies, potentially stratifying patients into risk categories. Recent research in ccRCC has already demonstrated that SHC1 serves as an independent prognostic factor, with high expression correlating with poorer survival outcomes .

Second, for companion diagnostics in immunotherapy, SHC1 antibody-based assays could predict response to immune checkpoint inhibitors. Data shows patients with low SHC1 expression exhibit significantly higher immunophenoscores across multiple CTLA4/PD1 subgroups, suggesting better potential responses to immunotherapy . This could help in patient selection for clinical trials and eventual therapeutic decisions.

Third, for monitoring treatment response, sequential liquid biopsy analysis using SHC1 antibodies might detect circulating tumor cells or exosomes expressing SHC1, potentially serving as a non-invasive method to track disease progression or treatment efficacy. Fourth, for therapeutic development, SHC1-targeting approaches could include antibody-drug conjugates directed against cancer cells with high SHC1 expression or bispecific antibodies linking SHC1-expressing tumor cells to immune effector cells.

Finally, for immunomodulatory strategies, given SHC1's association with immune infiltration and escape mechanisms , combination therapies targeting SHC1 signaling alongside existing immunotherapies could potentially overcome resistance mechanisms. As research continues to elucidate SHC1's role in specific cancer contexts, antibody-based applications will likely expand from purely research tools to clinically relevant applications in precision oncology.

What are the key research questions that remain unanswered about SHC1 function that could be addressed using antibody-based approaches?

Despite extensive research on SHC1, several critical questions remain unanswered that could be addressed using antibody-based approaches. First, the context-specific roles of different SHC1 isoforms (p46, p52, p66) in various cancer types require further elucidation. While some evidence suggests the p52 isoform contributes to breast cancer initiation , comprehensive analysis across cancer types using isoform-specific detection methods is needed. Antibody-based approaches combining immunoprecipitation with mass spectrometry could identify isoform-specific interaction partners in different cellular contexts.

Second, the dynamic regulation of SHC1 phosphorylation under various stimuli and stress conditions remains incompletely understood. Phospho-specific antibodies targeting different SHC1 phosphorylation sites could reveal activation patterns in response to growth factors, oxidative stress, or metabolic changes. Time-course experiments with such antibodies would map phosphorylation kinetics and their correlation with downstream signaling events.

Third, SHC1's subcellular localization changes during different cellular processes require further investigation. Immunofluorescence with SHC1 antibodies combined with super-resolution microscopy could track SHC1 trafficking between cellular compartments during signaling, potentially revealing novel regulatory mechanisms.

Fourth, the mechanistic basis for SHC1's association with immune infiltration and escape in tumors needs clarification . Multiplex immunohistochemistry with SHC1 antibodies alongside immune cell markers could map spatial relationships between SHC1-expressing tumor cells and immune populations within the tumor microenvironment.

Finally, the potential role of SHC1 in therapy resistance mechanisms remains largely unexplored. Antibody-based approaches comparing SHC1 expression and phosphorylation before and after treatment could identify adaptive changes contributing to resistance. These research directions would significantly advance our understanding of SHC1 biology and potentially reveal new therapeutic opportunities.